Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30807386 | 1.00 | CYP3A4 (0.51) | CYP3A4TAAR1AKR1C3AKR1C2ALDH1A1 | |
| SCHEMBL10863112 | 0.90 | MAPT (0.44) | CYP3A4TAAR1AKR1C3AKR1C2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28274376 | 0.86 | CYP3A4 (0.65) | CYP3A4TAAR1AKR1C3AKR1C2ALDH1A1 | |
| SCHEMBL25281976 | 0.82 | CYP3A4 (0.76) | CYP3A4TAAR1HSD17B10MAPTSMN1; SMN2 | |
| SCHEMBL11328148 | 0.82 | HSD17B10 (0.57) | CYP3A4TAAR1ALDH1A1HSD17B10KDM4E | |
| SCHEMBL14647017 | 0.80 | HMGCR (0.42) | CYP3A4AKR1C3AKR1C2ALDH1A1HPGD | |
| SCHEMBL8153869 | 0.79 | TAAR1 (0.62) | CYP3A4TAAR1ALDH1A1HSD17B10KDM4E | |
| SCHEMBL16527052 | 0.77 | CYP3A4 (0.49) | CYP3A4TAAR1ALDH1A1HSD17B10KDM4E | |
| SCHEMBL14755675 | 0.77 | NPSR1 (0.49) | TAAR1ALDH1A1HSD17B10KDM4EMAPT | |
| SCHEMBL16527146 | 0.76 | CYP3A4 (0.47) | CYP3A4TAAR1ALDH1A1HSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028600-A1 | TRANSAMINASE POLYPEPTIDES | CODEXIS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12448611-B2 | Transaminase polypeptides | CODEXIS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-12378537-B2 | Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs | CODEXIS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-12305201-B2 | Engineered biocatalysts and methods for synthesizing chiral amines | CODEXIS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20250101389-A1 | BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF SUBSTITUTED LACTAMS | CODEXIS INC (US) | 2025-03-27 | — | — | US | disclosed |
| US-12163162-B2 | Biocatalysts and methods for the synthesis of substituted lactams | CODEXIS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240150732-A1 | TRANSAMINASE POLYPEPTIDES | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2024-05-09 | — | — | US | disclosed |
| US-11939602-B2 | Transaminase polypeptides | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2024-03-26 | — | — | US | disclosed |
| WO-2024044657-A1 | BIOCATALYSTS AND METHODS THEREOF | TESARO, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20240026401-A1 | ENGINEERED BIOCATALYSTS AND METHODS FOR SYNTHESIZING CHIRAL AMINES | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2024-01-25 | — | — | US | disclosed |
| WO-2013036861-A1 | BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF SUBSTITUTED LACTAMS | CODEXIS, INC (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2012024100-A2 | PROCESS FOR PREPARING AMINOCYCLOHEXYL ETHER COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2012-02-23 | — | — | WO | disclosed |
| WO-2012024104-A2 | BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF (1R,2R)-2-(3,4-DIMETHOXYPHENETHOXY)CYCLOHEXANAMINE | CODEXIS, INC. (US) | 2012-02-23 | — | — | WO | disclosed |
| WO-2011159910-A2 | BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF (S)-3-(1-AMINOETHYL)-PHENOL | CODEXIS, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| EP-2385983-A2 | TRANSAMINASE POLYPEPTIDES | Codexis, Inc. (US) | 2011-11-16 | — | — | EP | disclosed |
| US-D646886-S1 | Tip of an umbrella | Pro Performance Sports, L.L.C. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100209981-A1 | TRANSAMINASE POLYPEPTIDES | CODEXIS, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| WO-2010081053-A2 | TRANSAMINASE POLYPEPTIDES | CODEXIS, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| EP-1075534-B1 | IMPROVEMENTS IN THE ENZYMATIC SYNTHESIS OF CHIRAL AMINES | CELGRO (US) | 2005-05-11 | — | — | EP | disclosed |
| US-6133018-A | Enzymatic synthesis of chiral amines using -2-amino propane as amine donor | CELGRO (US) | 2000-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101389-A1 | BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF SUBSTITUTED LACTAMS | BCAT1, GOT1, OAT | CYP3A4 533/4885TAAR1 2941/4885AKR1C3 818/4885 |
| US-20260028600-A1 | TRANSAMINASE POLYPEPTIDES | GOT1, OAT, PEPD | CYP3A4 65/4885TAAR1 890/4885AKR1C3 1409/4885 |
| US-12163162-B2 | Biocatalysts and methods for the synthesis of substituted lactams | BCAT1, GOT1, OAT | CYP3A4 533/4885TAAR1 2941/4885AKR1C3 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.